Companies › Byondis
2 active drug programs in 3 registered trials: 3 Phase 1; Oncology; next expected readout Dec 2026.
Open in Phaseline: competitors, likelihood bands and readouts Company report
| Drug | Target | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|
| Rituximab (BYON4228) B-lymphocyte antigen CD20 binding agent | MS4A1, SIRPA | Phase 1 | Lymphoma; Solid Tumor | Dec 2026 |
| BYON4413 | – | Phase 1 | Relapsed / Refractory AML | – |
| Registry id | Drug | Phase | Conditions | Area | Expected readout |
|---|---|---|---|---|---|
| NCT06359002 | BYON4413 | Phase 1 | Relapsed / Refractory AML | Oncology | Sep 2025 |
| NCT05737628 | Rituximab (BYON4228) | Phase 1 | Lymphoma | Oncology | Feb 2026 |
| NCT06932952 | Rituximab (BYON4228) | Phase 1 | Solid Tumor | Oncology | Dec 2026 |
Roche Biocad Acerta Pharma FBD Biologics Regeneron Pharmaceuticals Sandoz Celltrion TG Therapeutics Genmab Novartis
Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.